Bioventus Stock Performance
| BVS Stock | USD 6.26 0.23 3.54% |
The firm shows a Beta (market volatility) of 1.58, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bioventus will likely underperform. At this point, Bioventus has a negative expected return of -0.25%. Please make sure to confirm Bioventus' potential upside, as well as the relationship between the rate of daily change and relative strength index , to decide if Bioventus performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Bioventus has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in August 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (3.54) | Five Day Return (9.93) | Year To Date Return (41.11) | Ten Year Return (67.41) | All Time Return (67.41) |
1 | Bioventus Q1 Earnings and Revenues Surpass Estimates | 05/06/2025 |
2 | Q1 2025 Bioventus Inc Earnings Call Transcript | 05/07/2025 |
3 | Aurelia Metals And 2 Other ASX Penny Stocks To Consider | 05/22/2025 |
4 | Disposition of 18625 shares by Mark Singleton of Bioventus subject to Rule 16b-3 | 05/30/2025 |
5 | Disposition of 26493 shares by Beyer Pat of Bioventus subject to Rule 16b-3 | 06/02/2025 |
6 | Acquisition by Beyer Pat of 32282 shares of Bioventus subject to Rule 16b-3 | 06/03/2025 |
7 | Bravura Solutions Limited Insider Damien Leonard Buys 26,168 Shares | 06/04/2025 |
8 | Disposition of 7575 shares by Bartholdson John A. of Bioventus subject to Rule 16b-3 | 06/06/2025 |
9 | Do Options Traders Know Something About Bioventus Stock We Dont | 06/13/2025 |
10 | BVS Investors Await Craig-Hallum Meeting in Chicago BVS Stock News | 06/18/2025 |
11 | Head to Head Analysis NeuroMetrix versus Bioventus | 07/01/2025 |
12 | With 36 percent stake, Bioventus Inc. seems to have captured institutional investors interest | 07/10/2025 |
13 | Analysts Expect Bioventus Inc. To Breakeven Soon | 07/18/2025 |
| Begin Period Cash Flow | 37 M | |
| Total Cashflows From Investing Activities | 23 M |
Bioventus | Build AI portfolio with Bioventus Stock |
Bioventus Relative Risk vs. Return Landscape
If you would invest 750.00 in Bioventus on April 20, 2025 and sell it today you would lose (124.00) from holding Bioventus or give up 16.53% of portfolio value over 90 days. Bioventus is generating negative expected returns assuming volatility of 2.9837% on return distribution over 90 days investment horizon. In other words, 26% of stocks are less volatile than Bioventus, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Bioventus Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bioventus' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bioventus, and traders can use it to determine the average amount a Bioventus' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0826
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BVS |
Estimated Market Risk
| 2.98 actual daily | 26 74% of assets are more volatile |
Expected Return
| -0.25 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bioventus is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bioventus by adding Bioventus to a well-diversified portfolio.
Bioventus Fundamentals Growth
Bioventus Stock prices reflect investors' perceptions of the future prospects and financial health of Bioventus, and Bioventus fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bioventus Stock performance.
| Return On Equity | -0.2 | ||||
| Return On Asset | 0.0333 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | 0.04 % | ||||
| Current Valuation | 758.72 M | ||||
| Shares Outstanding | 66.36 M | ||||
| Price To Earning | 6.96 X | ||||
| Price To Book | 2.80 X | ||||
| Price To Sales | 0.73 X | ||||
| Revenue | 573.28 M | ||||
| Gross Profit | 382.9 M | ||||
| EBITDA | (49.55 M) | ||||
| Net Income | (33.54 M) | ||||
| Cash And Equivalents | 34.36 M | ||||
| Cash Per Share | 0.56 X | ||||
| Total Debt | 335.63 M | ||||
| Debt To Equity | 1.17 % | ||||
| Current Ratio | 0.94 X | ||||
| Book Value Per Share | 2.24 X | ||||
| Cash Flow From Operations | 38.8 M | ||||
| Earnings Per Share | (0.48) X | ||||
| Market Capitalization | 415.4 M | ||||
| Total Asset | 727.96 M | ||||
| Retained Earnings | (355.08 M) | ||||
| Working Capital | 65.21 M | ||||
About Bioventus Performance
Assessing Bioventus' fundamental ratios provides investors with valuable insights into Bioventus' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Bioventus is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 182.40 | 121.15 | |
| Return On Tangible Assets | (0.11) | (0.11) | |
| Return On Capital Employed | (0.02) | (0.02) | |
| Return On Assets | (0.05) | (0.05) | |
| Return On Equity | (0.23) | (0.24) |
Things to note about Bioventus performance evaluation
Checking the ongoing alerts about Bioventus for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bioventus help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bioventus generated a negative expected return over the last 90 days | |
| Bioventus has high likelihood to experience some financial distress in the next 2 years | |
| Bioventus has 335.63 M in debt with debt to equity (D/E) ratio of 1.17, which is OK given its current industry classification. Bioventus has a current ratio of 0.92, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for Bioventus to invest in growth at high rates of return. | |
| The entity reported the last year's revenue of 573.28 M. Reported Net Loss for the year was (33.54 M) with profit before taxes, overhead, and interest of 382.9 M. | |
| About 72.0% of Bioventus shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Analysts Expect Bioventus Inc. To Breakeven Soon |
- Analyzing Bioventus' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bioventus' stock is overvalued or undervalued compared to its peers.
- Examining Bioventus' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bioventus' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bioventus' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bioventus' stock. These opinions can provide insight into Bioventus' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Bioventus Stock Analysis
When running Bioventus' price analysis, check to measure Bioventus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioventus is operating at the current time. Most of Bioventus' value examination focuses on studying past and present price action to predict the probability of Bioventus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioventus' price. Additionally, you may evaluate how the addition of Bioventus to your portfolios can decrease your overall portfolio volatility.